<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339024</url>
  </required_header>
  <id_info>
    <org_study_id>2016/45</org_study_id>
    <secondary_id>2015-004463-37</secondary_id>
    <nct_id>NCT03339024</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study</brief_title>
  <official_title>Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: Follow-up of a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lade Addiction Treatment Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an assessment of the long-term effect of oxytocin nasal spray on alcohol
      withdrawal and dependence in adults admitted for detoxification of alcohol after 60 days and
      1 year. It is a follow-up study of a placebo-controlled randomized controlled study where
      subjects used oxytocin nasal spray during acute withdrawal and the following 4 weeks in an
      outpatient setting. Half of the participants have received oxytocin nasal spray, the other
      half placebo nasal spray (NCT02903251). (added March 2019: 24 patients were available for
      1-year follow-up)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol intake</measure>
    <time_frame>60 days</time_frame>
    <description>using self-reported alcohol use (days used and alcohol units)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol intake</measure>
    <time_frame>1 year</time_frame>
    <description>using the Timeline Follow-back method and phosphatidylethanol (PEth) blood test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>60 days</time_frame>
    <description>self-reported sleeping hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>1 year</time_frame>
    <description>self-reported sleeping hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of rehospitalisations and readmissions to treatment for substance use disorders</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Alcoholism</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.
Day 3-30:Self-administered intranasal spray as needed, max thrice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.
Day 3-30: Self-administered intranasal spray as needed, max thrice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal oxytocin spray</intervention_name>
    <description>6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.</description>
    <arm_group_label>oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intranasal spray without oxytocin</intervention_name>
    <description>6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participants in the RCT (NCT02903251) who completed the study

        Exclusion Criteria:

          -  participants in the RCT (NCT02903251) who did not complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Spigset, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lade Addiction Treatment Center</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Melby K, Fasmer OB, Henriksen TE, Gr√•we RW, Aamo TO, Spigset O. Actigraphy assessment of motor activity and sleep in patients with alcohol withdrawal syndrome and the effects of intranasal oxytocin. PLoS One. 2020 Feb 13;15(2):e0228700. doi: 10.1371/journal.pone.0228700. eCollection 2020.</citation>
    <PMID>32053696</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>Administration, Intranasal</keyword>
  <keyword>Ethanol</keyword>
  <keyword>Follow-up Studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

